These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30606813)

  • 1. Histamine and diabetic nephropathy: an up-to-date overview.
    Pini A; Verta R; Grange C; Gurrieri M; Rosa AC
    Clin Sci (Lond); 2019 Jan; 133(1):41-54. PubMed ID: 30606813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
    Fabris B; Candido R; Armini L; Fischetti F; Calci M; Bardelli M; Fazio M; Campanacci L; Carretta R
    J Hypertens; 1999 Dec; 17(12 Pt 2):1925-31. PubMed ID: 10703891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue expression of tubular injury markers is associated with renal function decline in diabetic nephropathy.
    Hwang S; Park J; Kim J; Jang HR; Kwon GY; Huh W; Kim YG; Kim DJ; Oh HY; Lee JE
    J Diabetes Complications; 2017 Dec; 31(12):1704-1709. PubMed ID: 29037450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis.
    Hallow KM; Gebremichael Y; Helmlinger G; Vallon V
    Am J Physiol Renal Physiol; 2017 May; 312(5):F819-F835. PubMed ID: 28148531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histamine H
    Pini A; Grange C; Veglia E; Argenziano M; Cavalli R; Guasti D; Calosi L; Ghè C; Solarino R; Thurmond RL; Camussi G; Chazot PL; Rosa AC
    Pharmacol Res; 2018 Feb; 128():18-28. PubMed ID: 29309903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.
    Petrica L; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Vlad D; Popescu R; Velciov S; Gluhovschi C; Bob F; Ursoniu S; Petrica M; Jianu DC
    J Diabetes Complications; 2015 Mar; 29(2):230-7. PubMed ID: 25511877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podocyte hypertrophy in diabetic nephropathy.
    Kim NH
    Nephrology (Carlton); 2005 Oct; 10 Suppl():S14-6. PubMed ID: 16174280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proximal tubule in the pathophysiology of the diabetic kidney.
    Vallon V
    Am J Physiol Regul Integr Comp Physiol; 2011 May; 300(5):R1009-22. PubMed ID: 21228342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells.
    Subathra M; Korrapati M; Howell LA; Arthur JM; Shayman JA; Schnellmann RG; Siskind LJ
    Am J Physiol Renal Physiol; 2015 Aug; 309(3):F204-15. PubMed ID: 26041445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt signaling and podocyte dysfunction in diabetic nephropathy.
    Bose M; Almas S; Prabhakar S
    J Investig Med; 2017 Dec; 65(8):1093-1101. PubMed ID: 28935636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The mechanisms responsible for the development of diabetic nephroangiopathy].
    Saltykov BB
    Arkh Patol; 2008; 70(5):38-42. PubMed ID: 19137784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glomerular filtration rate in early diabetes: ongoing discussions of causes and mechanisms.
    Frische S
    J Nephrol; 2011; 24(5):537-40. PubMed ID: 21887674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of the diabetic kidney.
    Vallon V; Komers R
    Compr Physiol; 2011 Jul; 1(3):1175-232. PubMed ID: 23733640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement deposition on renal histopathology of patients with diabetic nephropathy.
    Sun ZJ; Li XQ; Chang DY; Wang SX; Liu G; Chen M; Zhao MH
    Diabetes Metab; 2019 Sep; 45(4):363-368. PubMed ID: 30243617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptors: sensing and reacting to diabetic injury in the kidney.
    Lin M; Tang SC
    Nephrol Dial Transplant; 2014 Apr; 29(4):746-54. PubMed ID: 24203812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
    Steinke JM; Mauer M;
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperfiltration and diabetic nephropathy: is it the beginning? Or is it the end?
    Castellino P; Shohat J; DeFronzo RA
    Semin Nephrol; 1990 May; 10(3):228-41. PubMed ID: 2190280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypolipidemic and Antioxidant Properties of Oryzanol Concentrate in Reducing Diabetic Nephropathy via SREBP1 Downregulation Rather than β-Oxidation.
    G B; V G; T S; A S MK; C HK; G SK
    Mol Nutr Food Res; 2018 Apr; 62(8):e1700511. PubMed ID: 29469229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.